Hovione to ramp up output of Ligand's Captisol for COVID-19 treatment

Hovione has signed an agreement to significantly increase production of Ligand Pharmaceuticals' Captisol excipient, used in Gilead's remdesivir COVID-19 treatment, with monthly output soon matching previous annual production.

“Hovione will soon be producing per month the quantity it usually produces in one year.”doi.org

• 1 source
• doi.orgHovione warp-speeds Ligand’s excipientRick MullinSep 28, 2020

Summarized from public sources; check the original articles before acting on it.